Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Palmitic Acid-Triggerd B7H3 Palmitoylation Promotes Immune Escape

ABSTRACT:

B7H3 (CD276), a key immune checkpoint molecule that is overexpressed in tumors, plays a central role in cancer progression, making it a highly promising and specific therapeutic target. Here, we discovered that the cellular metabolite palmitic acid contributes to the development of an immunosuppressive microenvironment in colorectal cancer by triggering the palmitoylation of B7H3. Mechanistically, the palmitoyltransferase ZDHHC24 catalyzes the palmitoylation of B7H3 at Cys496, preventing its binding to the autophagy adaptor protein SQSTM1/p62 and inhibiting autophagic degradation. Using spectral flow techniques, we demonstrated that the mutation of this palmitoylation site restored CD8+ T cell antitumor activity. Additionally, CD8+ T cells also showed enhanced antitumor activity in a Zdhhc24-deficient colitis-associated colorectal (CAC) carcinogenesis mouse model. Furthermore, we developed a small-molecule peptide that enhances CD8+ T cell function by blocking the interaction between ZDHHC24 and B7H3, which works synergistically with anti-PD-1 therapy. In conclusion, our study revealed that B7H3 C496 palmitoylation is a critical immunosuppressive factor in colorectal cancer and represents a potential target for malignant immunotherapy.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase

PROVIDER: MTBLS12300 | MetaboLights | 2025-12-03

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	neg_MSI_H_1.raw	Raw
	neg_MSI_H_10.raw	Raw
	neg_MSI_H_2.raw	Raw
	neg_MSI_H_3.raw	Raw
	neg_MSI_H_4.raw	Raw

Items per page:

1 - 5 of 52

Similar Datasets

MGAT1-Mediated Glycosylation Orchestrates Immune Checkpoints and Antitumor Immunity

Project description:Despite the widespread application of immunotherapy, treating immune-cold tumors remains a significant challenge in cancer therapy. Using multiomic spatial analyses and experimental validation, we have identified MGAT1, a glycosyltransferase, as a pivotal factor governing tumor immune response. Overexpression of MGAT1 leads to immune evasion due to aberrant elevation of CD73 membrane translocation, which suppresses CD8+ T cell function, especially in immune-cold triple-negative breast cancer (TNBC). Mechanistically, addition of N-acetylglucosamine to CD73 by MGAT1 enables the CD73 dimerization necessary for CD73 loading onto VAMP3, ensuring membrane fusion. We further show that THBS1 is an upstream etiological factor orchestrating the MGAT1-CD73-VAMP3-adenosine axis in suppressing CD8+ T cell antitumor activity. Spatial transcriptomic profiling reveals spatially resolved features of interacting malignant and immune cells pertaining to expression levels of MGAT1 and CD73. In preclinical models of TNBC, W-GTF01, a newly developed inhibitor, specifically blocked the MGAT1-catalyzed CD73 glycosylation, sensitizing refractory tumors to anti-PD-L1 therapy via restoring capacity to elicit a CD8+ IFNγ-producing T cell response. Collectively, our findings uncover a strategy for targeting the immunosuppressive molecule CD73 by inhibiting MGAT1.

2025-05-07 | PXD055157 | Pride

RNA-seq analysis reveals dysregulated pathways in CAFs following NPs treatment.

Project description:Cancer-associated fibroblasts (CAFs) contribute to immunotherapy resistance in colorectal cancer (CRC) by creating physical barriers and fostering an immunosuppressive microenvironment, critically influencing tumor development and metastasis.Nowadays, nanotherapy has been extensively explored in oncology for its dual capabilities in cancer targeted treatment.However, the mechanisms by which nanoparticles (NPs) exert their antitumor effects through targeting and eliminating CAFs remain incompletely understood.In this study,NPs modulated intrinsic signaling pathways in CAFs, leading to altered chemokine secretion profiles. This modification enhanced dendritic cell maturation and promoted CD8+ T cell activation and functionality, ultimately amplifying the anti-tumor immune response to suppress CRC progression.

2025-12-24 | GSE301220 | GEO

In situ delivery of mRNA-encoded Gasdermin E promotes antitumor immunity via creatine-elicited type Ⅰ interferon signaling in monocytes

Project description:Tumor microenvironment is highly immunosuppressive. Tumor immunotherapy aims to reverse the immunosuppressive tumor microenvironment, activating antitumor immune response, which becomes a hotspot in tumor therapy. mRNA lipid nanoparticle based gene therapy represents a promising strategy for tumor immunotherapy. Identifying novel mRNA target is critical for improving the effect of in vivo gene immunotherapy for cancer. Pyroptosis obtains the key characteristics of immunologic cell death, and GSDME is an essential effector molecule triggering pyroptosis. Here, we synthetized mRNA encoding GSDME encapsulated by LNP (LNP-Gsdme). In situ delivery of LNP-Gsdme through intratumoral injection suppressed tumor growth, boosting monocytes infiltration and CD8+ T cell activation. Mechanistically, LNP-Gsdme-induced pyroptosis and immunogenic cell death in tumor cells, releasing creatine as a novel metabolic damage associated molecular pattern as well as a metabolite biomarker of ICD, eliciting cGAMP-STING-TBK1-IRF3-IFN-I signaling pathway in monocytes, then activating CD8+ T cells in the tumor microenvironment. Furthermore, creatine synergized the antitumor efficacy of LNP-Gsdme. Our observations in this study elucidate the effect and mechanisms of LNP-Gsdme in reshaping tumor immune microenvironment, providing novel insights and therapeutic approach into cancer therapy.

2025-03-24 | GSE272582 | GEO

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

Project description:Tumor escape mechanisms for immunotherapy include deficiencies in antigen presentation, diminishing adaptive CD8+ T cell antitumor activity. Although innate NK cells are triggered by loss of MHC class I, their response is often inadequate. To increase tumor susceptibility to both innate and adaptive immune elimination, we performed parallel genome-wide CRISPR-Cas9 screens. This identified all components, RNF31, RBCK1, and SHARPIN, of the linear ubiquitination chain assembly complex (LUBAC). Genetic and pharmacologic ablation of RNF31, an E3 ubiquitin ligase, strongly sensitized melanoma, breast and colorectal cancer cells to both NK and CD8+ T cell killing. This occurred in a TNF-dependent manner, causing loss of A20 and non-canonical IKK complexes from TNF Receptor Complex I. Corroborating this preclinically, a small molecule RNF31 inhibitor sensitized human colon carcinoma organoids to TNF and greatly enhanced immune bystander killing of antigen-loss and antigen presentation machinery-deficient tumor cells. These results merit exploration of RNF31 inhibition as a clinical pharmacological opportunity for immunotherapy-refractory cancers.

2022-05-30 | PXD029489 | Pride

The loss of RNA N 6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8 + T cell dysfunction and tumor growth

Project description:Tumor-associated macrophages (TAMs) can dampen the antitumor activity of T cells, yet the underlying mechanism remains incompletely understood. Here, we show that C1q+ TAMs are regulated by an RNA N6-methyladenosine (m6A) program and modulate tumor-infiltrating CD8+ T cells by expressing multiple immunomodulatory ligands. Macrophage-specific knockout of an m6A methyltransferase Mettl14 drives CD8+ T cell differentiation along a dysfunctional trajectory, impairing CD8+ T cells to eliminate tumors. Mettl14-deficient C1q+ TAMs show a decreased m6A abundance on and a higher level of transcripts of Ebi3, a cytokine subunit. In addition, neutralization of EBI3 leads to reinvigoration of dysfunctional CD8+ T cells and overcomes immunosuppressive impact in mice. We show that the METTL14-m6A levels are negatively correlated with dysfunctional T cell levels in patients with colorectal cancer, supporting the clinical relevance of this regulatory pathway. Thus, our study demonstrates how an m6A methyltransferase in TAMs promotes CD8+ T cell dysfunction and tumor progression.

2021-04-10 | GSE155098 | GEO

PIKfyve inhibition upregulates surface expression of MHC class I to enhance immune responses in cancer

Project description:Despite the remarkable clinical success of immunotherapies in a subset of cancer patients, many fail to respond to treatment and exhibit primary resistance. Here, we found thatgenetic or pharmacologic inhibitionof the lipid kinase PIKfyve, a regulator of autophagic flux and lysosomal biogenesis,upregulated surface expression of major histocompatibility complex class I (MHC-I) in cancer cells via impairing autophagic flux, resulting in enhanced cancer cell killing mediated by CD8+ T cells. Genetic depletion or pharmacologic inhibition of PIKfyve elevated tumor-specific MHC-I surface expression, reduced tumor proliferation, and increased intratumoral functional CD8+T cellsinsyngeneic mouse models. Importantly, enhanced antitumor responses by Pikfyve-depletion was CD8+T cell- and MHC-I-dependent,as CD8+ T cell depletion or B2m knockout rescued tumor growth. Furthermore, PIKfyve inhibition improved response to various immunotherapies, including immune checkpoint blockade (ICB), adoptive cell therapy, and therapeutic vaccines. High expression of PIKFYVE was also predictive of poor response to ICB and prognostic of poor survival in ICB-treated cohorts. Collectively, our findings show that targeting PIKfyve enhances immunotherapies by elevating surface expression of MHC-I in cancer cells, and PIKfyve inhibitors have potential as novel agents to increase immunotherapy response in cancer patients.

2023-11-13 | GSE235945 | GEO

Macrophage-specific BCAT1 deficiency drives lipid-associated immunosuppressive remodeling and promotes HCC progression

Project description:<p>The heterogeneous and immunosuppressive tumor microenvironment (TME) remains one of the major factors to the poor immunotherapeutic response in hepatocellular carcinoma (HCC). Tumor-associated macrophages (TAMs) are central orchestrators of this suppressive niche, yet the metabolic programs regulating their pro-tumorigenic functions remain incompletely understood. Here, we identify branched-chain amino acid transaminase 1 (BCAT1) as a metabolic checkpoint in TAMs that constrains tumor progression. Deficiency of BCAT1 in TAMs induces metabolic reprogramming, elevating intracellular crotonate levels and promoting histone crotonylation, which epigenetically activates lipid metabolism programs. This shift promotes TAM polarization toward a lipid-associated, immunosuppressive phenotype that accelerates HCC progression primarily by suppressing CD8+ T cell-mediated antitumor immunity</p>

2025-12-28 | MTBLS13579 | MetaboLights

The tumor intrinsic role of the m6A reader YTHDF2 in regulating immune evasion [scRNA-seq]

Project description:Tumors evade attacks from the immune system through various mechanisms. Here, we identify a component of tumor immune evasion mediated by YTH domain-containing family protein 2 (YTHDF2), a reader protein that usually destabilizes m6A-modified mRNA. Loss of tumoral YTHDF2 inhibits tumor growth and prolongs survival in immunocompetent tumor models. Mechanistically, tumoral YTHDF2 deficiency promotes the recruitment of macrophages via CX3CL1 and enhances mitochondrial respiration of CD8+ T cells by impairing tumor glycolysis metabolism. Tumoral YTHDF2 deficiency promotes inflammatory macrophage polarization and antigen presentation in the presence of IFN-γ. In addition, IFN-γ induces autophagic degradation of tumoral YTHDF2, thereby sensitizing tumor cells to CD8+ T cell-mediated cytotoxicity. Last, we identified a small molecule compound that preferentially induces YTHDF2 degradation, which shows a potent antitumor effect alone but a better effect when combined with anti-PD-L1 or anti-PD-1 antibodies. Collectively, YTHDF2 appears to be a tumor-intrinsic regulator that orchestrates immune evasion, representing a promising target for enhancing cancer immunotherapy.

2024-05-31 | GSE239426 | GEO

The tumor intrinsic role of the m6A reader YTHDF2 in regulating immune evasion [RNA-seq]

2024-05-31 | GSE239423 | GEO

The tumor intrinsic role of the m6A reader YTHDF2 in regulating immune evasion [bulk RNA-seq]

2024-05-31 | GSE256058 | GEO